Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

nts with ESRD on dialysis are usually associated with secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and the progression of renal failure. ESRD patients usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. The need for alternative phosphate-binding agents has long been recognized, especially given the increasing prevalence of ESRD as well as shortcomings with current therapies. Zerenex has the potential to be an effective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

The market for phosphate binders to treat hyperphosphatemia in ESRD patients in 2010 was approximately $750 million in the U.S. and is approaching $1.5 billion worldwide.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other signal transduction pathways, including the JNK pathway, believed to be associated with cell death, growth, differentiation and survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphate
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
(Date:3/30/2015)... March 29, 2015 A two-day workshop ... States and plenary talks by four leading photonics researchers ... + Optoelectronics next month in Prague, Czech Republic. ... 17 conferences alongside a two-day exhibition. Sponsored by ... the event will run 13-16 April in the Clarion ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an ... development by Shionogi & Co., Ltd., met its ... study (COMPOSE I) for the treatment of opioid-induced ... pain receiving opioid therapy. Study results showed that ... significantly improved the frequency of spontaneous bowel movement ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8
... SAN DIEGO, Sept. 10 Neurocrine Biosciences,Inc. (Nasdaq: ... at the Bear Stearns Healthcare Conference. The live presentation,takes ... Time (ET),/7:30 a.m. Pacific Time (PT). The presentation will ... website at, http://www.neurocrine.com If you are unable ...
... announced,today a civil settlement with the U.S. Department ... under the federal False Claims Act,relating to Anzemet(R) ... (API). The settlement relates to government claims ... in turn increased the cost of,government reimbursements for ...
... Calif., Sept. 10 /Xinhua-PRNewswire-FirstCall/,-- Kiwa Bio-Tech Products Group ... Green Food Association of the Agriculture Ministry,("CGFA") has ... CGFA,Recommend Brands." The vice president of CGFA, ... 13 million hm2 (hectares) of planting area in ...
Cached Biology Technology:Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association 2
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... BYU researchers coming down with the rhinovirus genome A new ... nearly half of all cold infections explains how and where ... for possible vaccines. The study is reported in the April ... . , "There are a lot of different approaches ...
... Japanese Association of Anatomists has chosen Springer to publish ... The first issue will be published at Springer in ... Wiley-Blackwell. Anatomical Science International focuses on ... include molecular, cellular, histological and gross anatomical studies. ...
... Wash. -- Single oxygen atoms dancing on a metal ... helped chemists better understand how water splits into oxygen ... a chemical reaction that had previously only been talked ... chemistry needed to generate hydrogen fuel from water or ...
Cached Biology News:Catching the common cold virus genome 2Anatomical Science International joins Springer's publishing program 2Dancing 'adatoms' help chemists understand how water molecules split 2Dancing 'adatoms' help chemists understand how water molecules split 3
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Biology Products: